Compare Air Products & Chemicals, Inc. (APD) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Air Products & Chemicals, Inc. vs BioNTech SE - ADR — how do they compare? Air Products & Chemicals, Inc. trades at $308.56 (market cap $68.63B), while BioNTech SE - ADR trades at $92.64 (market cap $23.31B). The key difference: Air Products & Chemicals, Inc. is far larger — about 2.9× BioNTech SE - ADR's market cap, and Air Products & Chemicals, Inc. pays a 2.35% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| APD | BNTX | |
|---|---|---|
Market Cap | $68.63B | $23.31B |
Sector | Basic Materials | Health |
52-Week High | $314.19 | $119.34 |
52-Week Low | $230.42 | $83.89 |
Enterprise Value | $85.80B | $6.60B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Air Products and Chemicals (APD) trades at $303.44, up 1.17% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The stock shows strong analyst support with a consensus price target of $346, though high valuation ratios like a P/E of 30.86 and EV/EBITDA of 50.36 raise concerns. Recent news highlights a major semiconductor supply deal in Taiwan and raised guidance after Q3 2026 results.
The outlook is mixed: positive momentum from contract wins and earnings performance offers upside, but negative net income margins and elevated debt levels pose risks. Investors should weigh growth catalysts against financial leverage and profitability challenges.
BioNTech (BNTX) trades at $93.67, up 2.72% today, with a bullish technical signal and strong analyst support. The stock faces fundamental challenges, including declining COVID-19 vaccine revenue and negative profitability, but holds a robust cash position of $16.78 billion. Recent news highlights leadership changes and pipeline advancements in oncology, with a consensus price target of $121.00 implying significant upside potential.
Outlook: Long-term growth hinges on oncology pipeline success, but near-term risks from vaccine demand volatility and net losses persist. Investment opportunity lies in discounted valuation relative to cash and pipeline assets, though execution risks and competitive pressures require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Air Products & Chemicals, Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Read more on APD →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
